1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Drugs In Development, 2022, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is divided into two categories cystic fibrosis (CF) bronchiectasis and non-CF bronchiectasis. Symptoms include chronic coughing, shortness of breath, chest pain, fatigue, weight loss and fever. Causes of bronchiectasis include inhaling foreign object, cystic fibrosis, GERD and weakness in immune system. Treatment includes antibiotics to fight infection, bronchodilators, expectorants and mucolytic agents.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Bronchiectasis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Bronchiectasis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Bronchiectasis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 7, 7, 1, 8 and 4 respectively.
Bronchiectasis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchiectasis (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Bronchiectasis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bronchiectasis (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bronchiectasis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bronchiectasis (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bronchiectasis (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bronchiectasis (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Bronchiectasis - Overview
- Bronchiectasis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Bronchiectasis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Bronchiectasis - Companies Involved in Therapeutics Development
- Bronchiectasis - Drug Profiles
- Bronchiectasis - Dormant Projects
- Bronchiectasis - Discontinued Products
- Bronchiectasis - Product Development Milestones
- Featured News & Press Releases
- May 17, 2022: Insmed presents new data on brensocatib at American Thoracic Society 2022 International Conference
- Apr 07, 2022: Renovion provides regulatory update and initiation of clinical program in non-CF bronchiectasis
- Feb 22, 2022: Armata Pharmaceuticals announces clearance of investigational new drug application to initiate phase 2 clinical trial of AP-PA02 in non-cystic fibrosis bronchiectasis
- Sep 21, 2021: Renovion and the COPD Foundation launch COPD and bronchiectasis development partnership to address unmet patient need
- Dec 02, 2020: Insmed announces initiation of phase 3 ASPEN study of brensocatib in patients with bronchiectasis
- Nov 15, 2020: SolAeroMed provides update on Phase II trial of S1226
- Nov 13, 2020: Insmed receives priority medicines (PRIME) designation from European Medicines Agency (EMA) for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
- Sep 30, 2020: Insmed highlights progress across portfolio and outlines growth strategy on brensocatib at R&D Day
- Sep 07, 2020: New England Journal of Medicine publishes positive results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis
- Jun 24, 2020: Positive Results from phase 2 WILLOW study of Brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ATS Virtual Clinical Trials Session
- Jun 08, 2020: Insmed receives FDA breakthrough therapy designation for Brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE)
- May 20, 2020: Insmed to showcase new brensocatib data at American Thoracic Society virtual clinical trials session
- Feb 03, 2020: Insmed announces positive top-line results from phase 2 WILLOW study of INS1007 in patients with Non-Cystic Fibrosis Bronchiectasis
- Jun 07, 2019: Polyphor presents new in-vivo efficacy and tolerability data for a potential inhaled administration of its lead antibiotic murepavadin at the European Cystic Fibrosis Conference
- Oct 12, 2017: Polyphor launches the development of an inhaled formulation of its antibiotic Murepavadin and joins a European consortium of leading hospitals and research institutions
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Bronchiectasis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Bronchiectasis - Dormant Projects, 2022
- Bronchiectasis - Discontinued Products, 2022
- Number of Products under Development for Bronchiectasis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Armata Pharmaceuticals Inc
- BioAegis Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici SpA
- Cila Therapeutics
- CSL Ltd
- Destiny Pharma Plc
- Haisco Pharmaceutical Group Co Ltd
- Helperby Therapeutics Group Ltd
- Insmed Inc
- Joincare Pharmaceutical Group Industry Co Ltd
- Kamada Pharmaceuticals
- Kyowa Kirin Co Ltd
- MDI Therapeutics Inc
- Metagone Biotech Inc
- Novabiotics Ltd
- Novartis AG
- OrPro Therapeutics Inc
- Parion Sciences Inc
- PureIMS BV
- Renovion Inc
- Santhera Pharmaceuticals Holding AG
- SolAeroMed Inc
- Spexis AG
- Suzhou Regend Therapeutics Co Ltd
- Therapeutic Systems Research Laboratories Inc
- Thirty Respiratory Ltd
- Vast Therapeutics Inc
- Zambon Co SpA
